Pfizer (PFE) is large-cap pharmaceutical company headquartered in Manhattan. It offers treatment drugs for conditions such as cardiovascular, pain and metabolism, cancer, inflammation, women’s health, rare diseases, and more. Selling their products from wholesalers, retailers, hospitals, government clinics, and pharmacies, PFE operates globally, with a market cap of $150.9 billion.
While many other pharma stocks have been notching impressive gains lately, that's not the case for Pfizer. PFE stock is down 34.8% in the last 52 weeks, including a decline of more than 7% in 2024. The stock is trading near its 52-week low of $25.61, set in early March.
